Quercetin‐3‐glucoside increases low‐density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture

By  

FEBS Open Bio, Vol. 4, Iss. 1, 2014-01 ,pp. : 755-762

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence

By Cicero Arrigo FG   Tartagni Elisa   Ertek Sibel  

Expert Opinion on Biological Therapy, Vol. 14, Iss. 6, 2014-06 ,pp. : 863-868

Informa Healthcare

Access to resources Recommend Favorite

Preferential apelin‐13 production by the proprotein convertase PCSK3 is implicated in obesity

By  

FEBS Open Bio, Vol. 3, Iss. 1, 2013-01 ,pp. : 328-333

John Wiley & Sons Inc

Access to resources Recommend Favorite

Highly Regulated Expression of Subtilisin-like Proprotein Convertase PACE4 (SPC4) during Dentinogenesis

By Akamatsu T.   Matsuda Y.   Tsumura K.   Tada J.   Parvin M.N.   Wei W.   Kanamori N.   Hosoi K.  

Biochemical and Biophysical Research Communications, Vol. 272, Iss. 2, 2000-06 ,pp. : 410-415

Elsevier

Access to resources Recommend Favorite

Multibranch and Pseudopeptide Approach for Design of Novel Inhibitors of Subtilisin Kexin Isozyme-1

By  

Protein and Peptide Letters, Vol. 13, Iss. 9, 2006-09 ,pp. : 863-876

Bentham Science Publishers

Access to resources Recommend Favorite